Coherus BioSciences director Tzoumakas to exit board
| CHRS Stock | USD 1.11 0.03 2.78% |
Slightly above 54% of Coherus BioSciences' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Coherus BioSciences suggests that some traders are interested. Coherus BioSciences' investing sentiment can be driven by a variety of factors including economic data, Coherus BioSciences' earnings reports, geopolitical events, and overall market trends.
Coherus |
Coherus BioSciences director Tzoumakas to exit board
Read at investing.com
 |
Coherus BioSciences Fundamental Analysis
We analyze Coherus BioSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Coherus BioSciences is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Coherus BioSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coherus BioSciences stock to make a market-neutral strategy. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics with similar companies.
Peers
Coherus BioSciences Related Equities
| TIL | Instil Bio | 4.04 | ||||
| NXTC | NextCure | 1.30 | ||||
| NUVB | Nuvation Bio | 0.51 | ||||
| ASMB | Assembly Biosciences | 0.69 | ||||
| ACHL | Achilles Therapeutics | 0.72 | ||||
| SPRO | Spero Therapeutics | 1.27 | ||||
| CTMX | CytomX Therapeutics | 1.45 | ||||
| BOLT | Bolt Biotherapeutics | 2.08 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.